Brentuximab Vedotin in Transplant-Naïve Patients with Relapsed or Refractory Hodgkin Lymphoma: Analysis of Two Phase I Studies

BACKGROUND. Brentuximab vedotin is an antibody-drug conjugate designed to selectively deliver monomethyl auristatin E, a microtubule-disrupting agent, to CD30-expressing cells. Brentuximab vedotin induces durable objective responses in patients with relapsed or refractory Hodgkin lymphoma (HL) after...

Fuld beskrivelse

Na minha lista:
Bibliografiske detaljer
Main Authors: Forero-Torres, Andres, Fanale, Michelle, Advani, Ranjana, Bartlett, Nancy L., Rosenblatt, Joseph D., Kennedy, Dana A., Younes, Anas
Format: Artigo
Sprog:Inglês
Udgivet: AlphaMed Press 2012
Fag:
Lymphoma
Online adgang:https://ncbi.nlm.nih.gov/pmc/articles/PMC3425525/
https://ncbi.nlm.nih.gov/pubmed/22855426
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1634/theoncologist.2012-0133
Tags: Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!

Lignende værker